We are live on ! Find out more
HUMA icon

Humacyte
HUMA

70 hedge funds and large institutions have $38.7M invested in Humacyte in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.54% less ownership

Funds ownership: 13.05% → 11.51% (-1.5%)

10% less funds holding

Funds holding: 78 → 70 (-8)

10% less capital invested

Capital invested by funds: $43.1M → $38.7M (-$4.48M)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

58% less call options, than puts

Call options by funds: $323K | Put options by funds: $767K

Holders
70
Holders Change
-8
Holders Change %
-10.26%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
24
Reduced
22
Closed
14
Calls
$323K
Puts
$767K
Net Calls
-$444K
Net Calls Change
+$30K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$755K
2
Marshall Wace
Marshall Wace
United Kingdom
+$513K
3
HLA
Hamilton Lane Advisors
Pennsylvania
+$202K
4
Simplex Trading
Simplex Trading
Illinois
+$156K
5
E
Ergoteles
New York
+$120K

Top Sellers

1
YCMGA
York Capital Management Global Advisors
New York
-$3.42M
2
UOC
UBS O'Connor
Illinois
-$1.94M
3
BlackRock
BlackRock
New York
-$710K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$369K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$246K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$32K +$18.1K +4,710 +92%
WAM
52
Wolverine Asset Management
Illinois
$31K -$3.83K -1,000 -9%
Ensign Peak Advisors
53
Ensign Peak Advisors
Utah
$28K +$2.19K +570 +7%
AIG
54
American International Group
New York
$27K +$453 +118 +1%
Deutsche Bank
55
Deutsche Bank
Germany
$23K -$4.53K -1,180 -14%
Zurich Cantonal Bank
56
Zurich Cantonal Bank
Switzerland
$16K – – –
AB
57
Amalgamated Bank
New York
$15K +$165 +43 +1%
TRCT
58
Tower Research Capital (TRC)
New York
$13K -$10.4K -2,707 -40%
Wells Fargo
59
Wells Fargo
California
$12K -$909 -237 -6%
Citigroup
60
Citigroup
New York
$10K -$4.02K -1,049 -25%
ODG
61
O'Dell Group
Ohio
$5K – – –
AIP
62
Ameritas Investment Partners
Nebraska
$4K – – –
AA
63
Addison Advisors
Vermont
$3K – – –
AWM
64
Avior Wealth Management
Nebraska
$3K – – –
CUAMC
65
China Universal Asset Management Company
China
$3K +$3.7K +965 New
Daiwa Securities Group
66
Daiwa Securities Group
Japan
$1K – – –
FIA
67
FNY Investment Advisers
New York
$1K – – –
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
$1K +$483 +126 +127%
WFA
69
Wipfli Financial Advisors
Wisconsin
$1K +$767 +200 New
Fidelity Investments
70
Fidelity Investments
Massachusetts
$1K +$1.17K +304 +400%
HF
71
HRT Financial
New York
– -$188K -58,632 Closed
CP
72
CenterBook Partners
Connecticut
– -$133K -41,470 Closed
JAIC
73
Josh Arnold Investment Consultant
Minnesota
– -$71K -22,000 Closed
CSS
74
Cubist Systematic Strategies
Connecticut
– -$63K -19,500 Closed
Jane Street
75
Jane Street
New York
– -$61K -19,040 Closed
1 2
3
4

HUMA Hedge Fund Activity: Q3 2022 in Review

70 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2022, worth a combined $38.7M — down 10% from $43.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of HUMA and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 24 added.

The largest buyer was Renaissance Technologies, adding an estimated $755K. The largest seller was York Capital Management Global Advisors, cutting an estimated $3.42M.

  • 70 institutional investors held Humacyte (HUMA) as of Q3 2022, down from 78 in Q2 2022.
  • Funds reported $38.7M of Humacyte stock for Q3 2022, down 10% quarter-over-quarter.
  • 8 funds opened new Humacyte positions in Q3 2022 and 14 closed out, a net change of -6 holders.
  • The largest Humacyte buyer in Q3 2022 was Renaissance Technologies, an estimated $755K added.
  • The largest Humacyte seller in Q3 2022 was York Capital Management Global Advisors, an estimated $3.42M sold.

Based on aggregated 13F filings for Q3 2022.